Skip to main content

Table 3 Difference in biochemical profile from baseline to 24 weeks

From: Safety and efficacy of Empagliflozin in Pakistani Muslim patients with type 2 diabetes (SAFE-PAK); a randomized clinical trial

Laboratory Parameters

Group A (n = 84)

Group B (n = 87)

Mean Difference ± SE (95% CI)

p-value

Mean Difference ± SE (95% CI)

p-value

ALP (IU/L)

3.82 ± 2.46(−2.21–9.85)

0.376

3.62 ± 2.25(− 1.89–9.12)

0.338

eGFR (mL/min/1.73m2)

−1.58 ± 2.79(− 8.40–5.24)

1.000

−3.24 ± 3.14(10.92–4.43)

0.916

Creatinine (mg/dl)

0.03 ± 0.01(− 0.01–0.06)

0.145

0.02 ± 0.02(0.04–0.07)

1.000

BUN (mg/dl)

1.60 ± 0.51(0.40–2.87)

0.005

1.54 ± 0.58(0.12–2.95)

0.028

TC (mg/dl)

5.78 ± 4.26(−4.60–16.2)

0.534

5.21 ± 4.41(−5.52–15.97)

0.721

TG (mg/dl)

17.83 ± 13.30(−14.70–50.39)

0.553

−1.94 ± 15.20(− 38.98–35.10)

1.000

Hb (g/dl)

1.51 ± 1.47(−5.10–2.10)

0.930

−1.25 ± 1.62(− 5.20–2.70)

1.000

WBC (103/μL)

0.42 ± 0.23(−0.14–0.98)

0.227

0.50 ± 0.19(0.04–0.96)

0.029

RBC (106/μL)

0.08 ± 0.07(−0.24–0.08)

0.664

0.10 ± 0.09(− 0.12–0.31)

0.798

Hematocrit (%)

−0.80 ± 0.57(− 2.19–0.60)

0.501

0.39 ± 0.71(− 1.34–2.11)

1.000

MCV (fL)

0.55 ± 1.17(− 2.33–3.42)

1.000

− 0.31 ± 1.12(− 3.03–2.42)

1.000

Platelets (103/μL)

31.1 ± 7.78(12.05–50.05)

< 0.001

25.33 ± 6.34(−9.84–40.82)

< 0.001

  1. BUN Blood Urea Nitrogen, eGFR estimated glomerular filtration rate, ALP Alkaline phosphatase, TC Total cholesterol, TG Triglycerides, Hb Hemoglobin, MCV Mean corpuscular volume, WBC White Blood Cells, RBC Red Blood Cells Group A-Empagliflozin; Group B-Standard Care
  2. Values are presented in n (%) or mean ± Standard deviation (median; range). Two-factor ANOVA with repeated measures analysis was performed to determine the mean difference in laboratory parameters in all patients who completed the study. P-value < 0.05 was considered as the level of significance